Sign in
IMMX Stock Price, Chart, Stats & News
Immix Biopharma, Inc.
Save
Immix Biopharma, Inc. (IMMX) does not currently pay a dividend.
636.50M
Market cap
–
Current P/E
–
Forward P/E
IMMX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.13% |
ROA | -28.08% |
ROE | -101.24% |
D/E | 0.01x |
Interest coverage ratio | – |
IMMX valuation
P/E | – |
P/S | – |
P/B | 3.33x |
P/CF | -13.04x |
P/FCF | -17.50x |
P/OCF | -13.04x |
PEG | 0.75x |
EV multiple | -17.82x |
About
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors.
Similar securities
Based on sector and market capitalization
Report issue